Evidence map›Paper›PMID 42473555›Full record

ReviewInternational journal of nanomedicine2026

Toward Safe and Effective Gene Therapy: Non-Viral Nanostructured Delivery Systems.

Fatemeh Madani, Elaheh Izadi, Maral Motamedi, Mazdak Ganjalikhani Hakemi, Zohreh Saltanatpour, Thomas J Webster, Seyed Farzad Mohammadi

Abstract readReview
In one paragraph

Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Fatemeh MadaniDepartment of Medical Nanotechnology, Tehran University of Medical Sciences, Tehran, Iran.ORCID 0000-0001-9535-2743
Elaheh IzadiTranslational Ophthalmology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Maral MotamediDepartment of Medical Nanotechnology, Tehran University of Medical Sciences, Tehran, Iran.
Mazdak Ganjalikhani HakemiRegenerative and Restorative Medicine Research Center (REMER), Research Institute for Health Sciences and Technologies (SABITA), Istanbul Medipol University, Istanbul, Turkey.
Zohreh SaltanatpourTranslational Ophthalmology Research Center, Tehran University of Medical Sciences, Tehran, Iran.ORCID 0000-0002-1616-9404
Thomas J WebsterDivision of Pre-College and Undergraduate Studies, Brown University, Providence, RI, USA.ORCID 0000-0002-2028-5969
Seyed Farzad MohammadiTranslational Ophthalmology Research Center, Tehran University of Medical Sciences, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gene therapy has emerged as a transformative strategy for treating a wide range of genetic and acquired disorders. Despite its potential, clinical translation is hindered by the limitations of viral vectors, including immunogenicity, insertional mutagenesis, limited cargo capacity, and production challenges. Consequently, non-viral gene delivery systems have gained increasing attention as safer, more versatile alternatives. These platforms, including lipid-based nanoparticles, polymers, dendrimers, inorganic nanocarriers, and hybrid systems, offer customizable physicochemical properties, scalable manufacturing, and reduced risk of adverse immune responses. This review systematically expresses recent advances in non-viral vectors, focusing on the key parameters that influence cellular uptake, endosomal escape, nuclear localization, and overall transfection efficiency in various disease, especially cancers. Additionally, we evaluate recent preclinical and clinical studies, highlighting promising translational outcomes and therapeutic applications. By comparing different non-viral strategies and discussing their mechanistic underpinnings, this review underscores the potential of non-viral vectors to overcome the inherent limitations of viral delivery and to drive the development of next-generation gene therapy approaches that are safer, more adaptable, and clinically relevant.

Indexed as

Genetic TherapyGene Transfer TechniquesNanostructuresAnimalsHumansNanomedicineNanoparticlesgene deliverygene therapynanomedicinenanoparticlesnon-viral vectors

Identifiers

PMID42473555
PMCPMC13380953

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.